Ars Pharmaceuticals, INC Form 4 insider transactions

RA Capital Management, L.P. and affiliated entities report the acquisition of a stock option for 30,000 shares of ARS Pharmaceuticals, Inc. (SPRY) with an exercise price of $10.54.

ARS Pharmaceuticals, Inc. reports that Director Rajeev Dadoo acquired 30,000 stock options on June 24, 2026, as detailed in a Form 4 filing.

ARS Pharmaceuticals, Inc. Director Pratik Shah acquired 30,000 stock options with an exercise price of $10.54.

ARS Pharmaceuticals, Inc. director Michael Kelly acquired 30,000 stock options with an exercise price of $10.54, vesting in full on June 24, 2027, or the 2027 annual meeting.

ARS Pharmaceuticals, Inc. reports that Director Saqib Islam acquired 30,000 stock options on June 24, 2026.

Peter A. Thompson, a Director at ARS Pharmaceuticals, Inc., acquired 30,000 stock options with an exercise price of $10.54.

ARS Pharmaceuticals Director Brent L. Saunders acquired 30,000 stock options with an exercise price of $10.54, vesting in full on June 24, 2027, or the 2027 annual meeting.

ARS Pharmaceuticals, Inc. reports that Director Phillip M. Schneider acquired 30,000 stock options with an exercise price of $10.54.

Laura Shawver, a Director at ARS Pharmaceuticals, Inc., acquired 30,000 stock options with an exercise price of $10.54.

Chief Commercial Officer Eric Karas exercised options and sold 25,000 shares of ARS Pharmaceuticals common stock.

Chief Legal Officer Alexander A. Fitzpatrick sold 3,355 shares of ARS Pharmaceuticals common stock under a pre-arranged trading plan.

ARS Pharmaceuticals' Chief Financial Officer, Kathleen D. Scott, was granted 240,000 stock options with an exercise price of $11.49, vesting over 48 months.

ARS Pharmaceuticals' Chief Commercial Officer, Eric Karas, was granted 240,000 stock options with an exercise price of $11.49, vesting monthly over four years starting January 1, 2026.

ARS Pharmaceuticals' Chief Legal Officer, Alexander A. Fitzpatrick, was granted 240,000 stock options with an exercise price of $11.49, vesting over 48 months.

ARS Pharmaceuticals' Chief Operating Officer, Brian Dorsey, was granted 240,000 stock options with an exercise price of $11.49, vesting over four years.

ARS Pharmaceuticals' Chief Business Officer, Justin Chakma, was granted 240,000 stock options with an exercise price of $11.49, vesting over 48 months.

Sarina Tanimoto, Chief Medical Officer of ARS Pharmaceuticals, acquired over 1 million stock options with a $11.49 exercise price, vesting monthly over four years.

ARS Pharmaceuticals, Inc. CEO Richard E. Lowenthal was granted stock options for 1,115,000 shares of common stock with a strike price of $11.49, vesting over 48 months.

ARS Pharmaceuticals' Chief Operating Officer, Brian Dorsey, exercised stock options and subsequently sold 21,828 shares of common stock.

ARS Pharmaceuticals' Chief Business Officer, Justin Chakma, sold all his directly held common stock after exercising options, totaling 166,380 shares.

ARS Pharmaceuticals Director Pratik Shah reported gifting 350,000 shares of common stock through two separate, pre-planned transactions.

ARS Pharmaceuticals' President and CEO, Richard E. Lowenthal, sold 50,000 shares of common stock for approximately $14.49 per share under a pre-arranged trading plan.

ARS Pharmaceuticals CFO Kathleen Scott exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

ARS Pharmaceuticals' Chief Medical Officer, Sarina Tanimoto, sold 50,000 shares of common stock for approximately $700,000 through a pre-arranged trading plan.

ARS Pharmaceuticals' Chief Commercial Officer, Eric Karas, executed a pre-planned sale of 15,000 common shares on July 1, 2025, following the exercise of stock options.

James E. Flynn, a director and 10% owner of ARS Pharmaceuticals, Inc., along with affiliated Deerfield entities, reported the sale of 740,149 shares of Class A Common Stock for approximately $13.66 million.

ARS Pharmaceuticals, Inc. Director Peter A. Thompson was granted 30,000 stock options with an exercise price of $17.26, with the beneficial economic interest designated for OrbiMed Private Investments VI, LP.

ARS Pharmaceuticals, Inc. Director Brent L. Saunders was granted 30,000 stock options with an exercise price of $17.26, vesting fully by June 25, 2026, or the 2026 annual meeting.

Phillip M. Schneider, a Director at ARS Pharmaceuticals, Inc., was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.

ARS Pharmaceuticals, Inc. Director Laura Shawver was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.